The Institute of Safe Medication Practices (ISMP), in its April 2013 report, revealed that 1,723 very alarming adverse events from July 1, 2011 to June 30, 2012 have been received by the Food and Drug Administration (FDA) involving incretin mimetic type of diabetes medications. A total of 831 cases were for pancreatitis, 105 cases for cancer of the pancreas, 32 cases for thyroid cancer, and 101 patients reported sensitivity reactions.
Of this number, 612 cases or over a third of all adverse reports were attributed to the Byetta injectable. This represents 263 cases of pancreatitis, 71 for pancreatic cancer, 95 for renal failure, and 41 for thyroid cancer.
It was noted by the ISMP that 63 percent of these adverse reports were not filed by medical practitioners but directly by patients. Further analysis by the group may not exactly be favorable to the Byetta drug. It was found out that for every 100,000 prescriptions, Byetta accounted for 40 cases which was very high compared to the other incretin-based medications.
Read More: Watchdog Finds Byetta FDA Complaints More Common Than For Other Diabetes Drugs
On May 9 a woman filed a lawsuit against drug makers Amylin Pharmaceuticals and Eli Lilly in federal court, alleging that the companies failed to adequately warn her about type 2 diabetes drug Byetta’s link to thyroid cancer, according to court documents for Childress v. Amylin Pharmaceuticals LLC, et al., No. 3:13-1114 (U.S. District Court for the Southern District of California). The Rottenstein Law Group LLP maintains a Byetta Lawsuits Center at http://www.byettalawsuits.us, which features comprehensive information about the drug and steps that need to be taken to file a lawsuit.
Elizabeth Childress was prescribed Byetta in January 2007 to treat her type 2 diabetes, and continued to take it through August of that year, according to court documents. In May 2011 she was diagnosed with thyroid cancer and attributes it to her use of Byetta, a drug that has also been linked to both thyroid cancer and pancreatic cancer in women.* Childress alleges that the drug makers were aware of the risks but did not notify patients of them.
“It is important that the drug makers are held accountable, if the allegations are true,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP.
Read more: Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports
As a diabetes medication, Byetta is injected to control the blood sugar in the body. This medication may aid the pancreas to produce insulin more efficiently. It is also considered as a short-acting form of exenatide. Incretin mimetics is a class of drugs exenatide belongs because it imitates the effects of incretins. Human-glucagon-like peptide-1 (GLP-1) is a form of incretins which is a hormone generated and released into the blood by the intestine in response to food. GLP-1 increases the secretion of insulin from the pancreas, slows absorption of glucose from the gut, and reduces the action of glucagon.
Byetta is a newly manufactured drug which was approved as treatment for type 2 diabetes in 2005. It is known as an incretin mimetic and is a synthetic version of a compound found in the venom of a Gila monster, a lizard in the south-western United States. Doctors wrote almost seven million Byetta prescriptions between 2005 and 2008.
There is a potential that Byetta may cause harm to some people, or simply people may become unsuitable for it. In case you experience any uncomfortable effects caused Byetta, it is very important to contact your healthcare provider as soon as possible. The Food and Drug Administration (FDA) has stated that pancreatitis symptoms got worse after the dose of Byetta was increased from five micrograms twice daily to ten micrograms two times a day. It has been reported that out of the 30 people using the medication, 21 of them have been hospitalized and five of these have been observed to developed serious health problems, such as dehydration, kidney failure, intestinal obstruction, tissue inflammation, and abnormal build-up of fluid in the abdomen.
One needs to go an ER immediately if you feel severe and persistent abdominal pain. If pancreatitis is suspected, exenatide should be discontinued and not started again until pancreatitis has been excluded.
Researches discovered that the use of Byetta may heighten your risk for pancreatic cancer, pancreatitis and thyroid problems. If you want to know more about Byetta and its side effects, there are substantial information found on the Byetta lawsuits blog.